Teduglutide Research Peptide (GLP-2 Analog) Supplier — UPOR Biotech
Teduglutide — a 33-amino-acid GLP-2 analogue ([Gly2]hGLP-2) with a single Ala²→Gly² substitution that confers DPP-IV resistance and an extended circulating half-life. An intestinotrophic GLP-2 receptor agonist that stimulates crypt cell proliferation, increases villus height and intestinal surface area, and enhances nutrient and fluid absorption. Research Grade (RUO) lyophilized powder — ≥98% HPLC from UPOR Biotech.
Request a QuoteProduct Overview
Teduglutide (CAS 197922-42-2, C₁₆₄H₂₅₂N₄₄O₅₅S, MW 3752.08 g/mol) is a 33-amino-acid analogue of human glucagon-like peptide-2 (GLP-2) engineered with a single Ala²→Gly² substitution ([Gly2]hGLP-2) that confers resistance to dipeptidyl peptidase-IV (DPP-IV) proteolysis. Native GLP-2 is rapidly inactivated by DPP-IV-mediated cleavage of the N-terminal Ala² residue, limiting its circulating half-life to minutes; the [Gly2] substitution blocks this cleavage site and extends the half-life to roughly 2–3 hours, enabling once-daily dosing in the clinical setting. Mechanistically, teduglutide is a potent GLP-2 receptor (GLP-2R) agonist with intestinotrophic (trophic) activity: it stimulates crypt cell proliferation, increases villus height and total intestinal surface area, enhances nutrient and fluid absorption, reduces intestinal permeability, and inhibits enterocyte apoptosis. This gut-growth mechanism is distinct from GLP-1, which is primarily insulinotropic — GLP-2 acts on intestinal growth and repair rather than glucose homeostasis. UPOR Biotech supplies teduglutide as a white to off-white lyophilized powder at ≥98% HPLC purity, suitable for in vitro and in vivo GLP-2R pharmacology, intestinal biology, and short bowel syndrome research.
As a leading research peptide supplier, UPOR Biotech positions teduglutide for the study of gastrointestinal biology, intestinal failure, and short bowel syndrome. Teduglutide is the active principle of the reference medicinal products Gattex (US) and Revestive (EU), approved for short bowel syndrome with intestinal failure; our material is supplied as Research Use Only (RUO) — not for human diagnostic or therapeutic use, for investigators developing intestinotrophic assays, GLP-2R pharmacodynamics studies, and intestinal growth/repair models. Bulk quantities and custom vial sizes are available. Certifications include ISO 9001, cGMP-compliant synthesis, and FDA facility registration, with full analytical documentation. Packaging is offered in 1 mg, 5 mg, 10 mg, and 50 mg sterile vials, each shipped with a certificate of analysis (COA), MSDS, HPLC chromatogram, and mass spectrometry data.
Teduglutide vs Native GLP-2 — [Gly2] DPP-IV Resistance for Extended Half-Life
When comparing teduglutide vs native GLP-2, the defining difference is a single amino-acid substitution: Ala²→Gly². Native human GLP-2 is cleaved and inactivated within minutes by DPP-IV, which hydrolyzes the peptide bond after the N-terminal Ala² residue. This short half-life makes unmodified GLP-2 impractical for sustained biological activity. The [Gly2] substitution removes the DPP-IV recognition site while preserving full GLP-2R agonism, converting the short-lived native hormone into a stable, clinically useful analogue with a ~2–3 hour half-life supporting once-daily administration. For researchers, this [Gly2] modification is the structural basis of teduglutide’s intestinotrophic potency and a model for DPP-IV-resistant peptide engineering.
Technical Specifications
| Property | Specification |
|---|---|
| Product Name | Teduglutide ([Gly2]hGLP-2) — Research Peptide |
| CAS Number | 197922-42-2 |
| Molecular Formula | C₁₆₄H₂₅₂N₄₄O₅₅S |
| Molecular Weight | 3752.08 g/mol |
| Sequence | [Gly2]hGLP-2 — 33-amino acid analogue of human GLP-2 |
| Amino Acid Residues | 33 |
| Key Modification | Ala²→Gly² ([Gly2] substitution) — DPP-IV resistance |
| Mechanism of Action | GLP-2R agonist — intestinotrophic (crypt proliferation, villus growth) |
| Purity (HPLC) | ≥98.0% |
| Peptide Content | ≥90% |
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in water, PBS, and aqueous buffers |
| Endotoxin | ≤1.0 EU/mg |
| Water Content | ≤5.0% |
| Counter-ion | Acetate |
| pH | 6.0 – 8.0 (reconstituted, 1 mg/mL) |
| Heavy Metals | ≤10 ppm |
| Synthesis Method | Solid-phase peptide synthesis (SPPS) — Fmoc chemistry |
| Half-Life | ~2–3 hours (DPP-IV resistant, reference) |
| Storage | -20°C, protected from light and moisture |
| Grade | Research Grade (RUO) |
| Applications | Short bowel syndrome, intestinal growth/repair, GLP-2R pharmacology |
| Certifications | ISO 9001, cGMP, FDA facility registration |
| Packaging | 1 mg / 5 mg / 10 mg / 50 mg vials |
| Shelf Life | 2 years (-20°C) |
| Disclaimer | Research Use Only (RUO) — not for human diagnostic or therapeutic use |
Key Benefits — Teduglutide (GLP-2 Analog)
DPP-IV-Resistant [Gly2] Modification
A single Ala²→Gly² substitution removes the DPP-IV cleavage site of native GLP-2, extending circulating half-life to ~2–3 hours. The structural basis of sustained intestinotrophic activity and a model for DPP-IV-resistant peptide design.
DPP-IV ResistantIntestinotrophic GLP-2R Activation
Potent GLP-2 receptor agonist stimulating crypt cell proliferation, villus height, and intestinal surface area — enhancing nutrient and fluid absorption while reducing permeability and apoptosis. Gut-growth mechanism distinct from insulinotropic GLP-1.
GLP-2R Agonist≥98% HPLC Purity — Lyophilized Research Peptide
White to off-white lyophilized powder at ≥98% HPLC purity with ≥90% peptide content, ≤1.0 EU/mg endotoxin, and acetate counter-ion. Fully characterized by HPLC, mass spectrometry, and COA for reproducible research.
≥98% HPLC33-aa Precise Sequence — Reference Standard
The exact 33-amino-acid [Gly2]hGLP-2 sequence (CAS 197922-42-2) matching the active principle of Gattex/Revestive. Ideal as a reference standard for method development, assay calibration, and comparative pharmacology.
Reference StandardApplications
Short Bowel Syndrome & Intestinal Failure Research
Model the intestinotrophic effects of GLP-2R activation in intestinal resection and adaptation studies; evaluate villus growth, crypt proliferation, and absorptive recovery.
Intestinal Epithelial & Villus Growth Studies
Quantify crypt cell proliferation, villus height, and mucosal surface area expansion in intestinal organoids, explants, and in vivo models.
Nutrient Absorption & Barrier Function Research
Assess glucose, fluid, and electrolyte transport, tight-junction integrity, and intestinal permeability modulation.
GLP-2 Receptor Pharmacology
Profile GLP-2R agonism, receptor binding kinetics, cAMP signaling, and structure-activity relationships of DPP-IV-resistant analogues.
Gut-Brain & Enteroendocrine Research
Investigate GLP-2 signaling crosstalk with enteroendocrine cells, GLP-1, PYY, and central appetite/satiety pathways.
Peptide Reference Standard & Assay Development
Serve as a characterized [Gly2]hGLP-2 reference standard for HPLC method validation, immunoassay calibration, and quality control.
Frequently Asked Questions
Teduglutide (CAS 197922-42-2) is a 33-amino-acid analogue of human GLP-2 with a single Ala²→Gly² substitution ([Gly2]hGLP-2). It acts as a GLP-2 receptor (GLP-2R) agonist with intestinotrophic activity — stimulating crypt cell proliferation, increasing villus height and intestinal surface area, enhancing nutrient and fluid absorption, reducing intestinal permeability, and inhibiting enterocyte apoptosis. This mechanism promotes growth and repair of the intestinal epithelium, distinct from the insulinotropic actions of GLP-1.
The sole structural difference is a single Ala²→Gly² substitution. Native GLP-2 is rapidly inactivated by DPP-IV, which cleaves the N-terminal Ala² residue and limits its half-life to minutes. The [Gly2] modification removes this cleavage site while preserving full GLP-2R agonism, extending the circulating half-life to ~2–3 hours and enabling once-daily dosing. This substitution is the basis of teduglutide’s stability and sustained intestinotrophic activity relative to unmodified GLP-2.
Primary research applications include short bowel syndrome and intestinal failure models, intestinal epithelial and villus growth studies, nutrient absorption and barrier function assays, GLP-2 receptor pharmacology, and gut-brain/enteroendocrine crosstalk investigations. Teduglutide also serves as a characterized [Gly2]hGLP-2 reference standard for assay development and method validation. Note our material is Research Use Only (RUO) — not for human diagnostic or therapeutic use.
Store lyophilized teduglutide at -20°C, protected from light and moisture, for long-term stability (shelf life 2 years). Reconstitute in sterile water, PBS, or a suitable aqueous buffer to the desired concentration; the peptide is freely soluble in aqueous solution. Avoid repeated freeze-thaw cycles, which can promote aggregation and reduce bioactivity — aliquot reconstituted solutions and store at -20°C to -80°C. Filter-sterilize if required for cell culture.
Every shipment includes a Certificate of Analysis (COA) documenting HPLC purity ≥98.0%, peptide content ≥90%, endotoxin ≤1.0 EU/mg, water content, and heavy metals ≤10 ppm, plus MSDS, HPLC chromatogram, ESI-MS mass spectrometry data, and amino acid analysis. Facilities operate under ISO 9001, cGMP-compliant synthesis, and FDA facility registration, with full lot traceability. All material is supplied Research Use Only (RUO).